DevCurationThe Premier Voice of the Entire Tech Ecosystem
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Latest
NEX-T AI Summit Brings Frontier Technology and Investment to StanfordNEX-T AI Summit Brings Frontier Technology and Investment to Stanford|Rowan Adds $1.545B in Credit for Hyperscale Data Centers|Trusted Space Acquires Falcon ExoDynamics for Space Autonomy|Yamaha Agrees to Acquire Disguise for Live Production|Inovalon Agrees to Acquire DrFirst for Medication Management|Ironleaf Backs HCS to Expand Hospital Coordination SoftwareIronleaf Backs HCS to Expand Hospital Coordination Software|eToro Agrees to Acquire LB Finanzas for Latin America|Ellipsis Health Acquires Kouper for AI Care Navigation|XRHealth Acquires PursueCare for Connected Addiction Care|Securitize Agrees to Buy River One for Asset-Backed Finance|NEX-T AI Summit Brings Frontier Technology and Investment to StanfordNEX-T AI Summit Brings Frontier Technology and Investment to Stanford|Rowan Adds $1.545B in Credit for Hyperscale Data Centers|Trusted Space Acquires Falcon ExoDynamics for Space Autonomy|Yamaha Agrees to Acquire Disguise for Live Production|Inovalon Agrees to Acquire DrFirst for Medication Management|Ironleaf Backs HCS to Expand Hospital Coordination SoftwareIronleaf Backs HCS to Expand Hospital Coordination Software|eToro Agrees to Acquire LB Finanzas for Latin America|Ellipsis Health Acquires Kouper for AI Care Navigation|XRHealth Acquires PursueCare for Connected Addiction Care|Securitize Agrees to Buy River One for Asset-Backed Finance
DevCuration

The premier voice of the tech ecosystem, from ideation to enterprise.

Explore

  • Where the Money Moved
  • Events
  • Articles & Analysis

Spotlights

  • Investor Spotlight
  • Company Spotlight
  • Frameworks

Company

  • About Us
  • Privacy Policy
  • Terms of Service
© 2026 DevCuration. All rights reserved.
TwitterLinkedIn
Logos provided by Logo.dev
Back to articles
March 04, 2026
•Jesse LandryJesse Landry

Precision BioSciences Raises $7.5M in Funding from TG Therapeutics

Precision BioSciences just reminded the biotech world that sometimes progress shows up as a quiet check with very loud implications. The Durham crew pulled in $7.5M tied to its partnership with TG Therapeutics. Not a flashy venture round. No confetti cannons. Just $5.25M in milestone cash and a $2.25M equity purchase at $11.17 per share tied to the progress of azercabtagene zapreleucel in a Phase 1 study for progressive multiple sclerosis. Translation for the non lab coat crowd. The science is moving forward and the partner is paying attention.

Credit to CEO Michael Amoroso for steering a company that understands the long game of biotech. Precision BioSciences was built on the ARCUS genome editing platform, a technology that sounds like a character in a sci fi novel but behaves more like a molecular surgeon. Small. Precise. Purpose built to edit DNA with intent. That kind of precision is not just branding. It is the business model.

Respect also goes to the architects who started this whole thing. Derek Jantz, Ph.D., Jeff Smith, Ph.D., and Matt Kane laid the scientific groundwork back in 2006. Jeff Smith now continues the mission as CRO Jeff Smith, Ph.D., pushing the platform forward while the company advances programs like PBGENE HBV and PBGENE DMD. Chronic hepatitis B and Duchenne muscular dystrophy are not small targets. They are the kind of diseases where a breakthrough does not just move a stock chart. It changes the trajectory of human lives.

Behind the curtain there is a leadership bench that knows how to translate deep science into real clinical momentum. CSO Cassie Gorsuch, Chief Development and Business Officer Cindy Atwell, CFO Alex Kelly, and SVP, Head of Clinical Development Murray Abramson are part of the engine room making sure the platform actually becomes medicine.

The azer cel program with TG Therapeutics is another smart move in the Precision playbook. Partnerships like this do 2 things. They validate the underlying science and they create non dilutive capital while the company advances its internal pipeline. Precision keeps focus on its in vivo ARCUS therapies while still collecting economic upside as partners move programs forward. That is not luck. That is strategic patience.

Genome editing is one of those arenas where hype tends to run faster than results. Precision BioSciences seems comfortable doing the opposite. Move the science. Hit the milestones. Collect the receipts. Repeat.

Back to all articles
Newsletter

Where the Money Moved

The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.

Subscribe to Where the Money Moved
Precisionbiosciences

Precisionbiosciences

ARCUS genome editing platform with in vivo programs PBGENE-HBV (chronic hepatitis B) and PBGENE-DMD (Duchenne muscular dystrophy); azer-cel (azercabtagene zapreleucel) Phase 1 in progressive MS via TG Therapeutics partnership

  • Durham
  • Founded 2006
Website

Key Executives

  • Derek Jantz (Co-Founder
  • Ph.D.)
+10 more (coming soon)

Related Articles

Funding Announcement
Mondrio Raises $3.75M for Agentic B2B Pricing Management
Nov 14, 2026
Funding Announcement
Zipline Raises $1.5B for Nationwide Drone Delivery
Nov 6, 2026
Funding Announcement
Fathers Beer Raises $2M for Retail Growth With Robert Irvine
Nov 5, 2026
Funding Announcement
Applied Compute Raises $350M for Enterprise AI Models
Nov 3, 2026
Funding Announcement
Crux Labs Raises $6M+ for Enterprise AI Agent Evaluation
Oct 29, 2026

More from Jesse Landry

Events
NEX-T AI Summit Brings Frontier Technology and Investment to Stanford
Nov 14, 2026
Funding Announcement
Rowan Adds $1.545B in Credit for Hyperscale Data Centers
Nov 14, 2026
Funding Announcement
Trusted Space Acquires Falcon ExoDynamics for Space Autonomy
Nov 14, 2026

Trending

News
Ironleaf Backs HCS to Expand Hospital Coordination Software
Nov 14, 2026
Company Spotlight
Nebuly Company Spotlight: Building Enterprise AI Measurement
Nov 13, 2026
View all posts